Vaporox Inc.

Vaporox Inc. is a health care startup founded in 2016, headquartered in the United States. The company's slogan, "Breakthrough technology for treating skin wounds," encapsulates its focus on addressing the significant challenge of non-healing skin wounds which impose substantial costs and human suffering. For instance, diabetic foot ulcers (DFUs) alone result in 108,000 lower limb amputations annually in the U.S., with estimated economic costs of $14.8 billion/year. Vaporox, Inc. has developed Vaporous Hyperoxia Therapy (VHT™), a new, patented, and FDA-510K-cleared technology capable of treating 7 different types of skin wounds. The technology, which utilizes ultrasonic waves to create microscopic particles containing water and an anti-microbial, has demonstrated substantial efficacy through real-world data from observational studies. Impressively, VHT has healed 90.7% of DFUs that had previously resisted standard wound care treatment, while also reducing costs compared to less-effective methods. Looking ahead, Vaporox is gearing up to commence a new round of field trials focused on healing DFUs and pressure ulcers in early 2019. The company's progress has attracted substantial investment, with a $2.00M Series A investment received on 01 August 2022. Overall, Vaporox Inc. is positioned at the forefront of advancing wound care technology, offering a compelling solution to a pressing health challenge with noteworthy potential for both financial return and societal impact.